Management of high grade primary cerebellar tumours

Abstract

Cerebellar high-grade gliomas (cHGG) are uncommon in
adults, making up only about 1% of all high-grade gliomas.
These tumours differ from supratentorial high-grade
gliomas (sHGG) in terms of epidemiology, molecular traits,
and the age of the patients. cHGG patients are typically
younger and show a higher frequency of
neurofibromatosis 1 (NF1) mutations, atypical RAS
mutations, and H3K27M mutations. Standard treatment
includes surgical resection followed by chemotherapy and
radiation. Recent studies emphasize the genetic differences
between cerebellar and supratentorial tumours, with new
treatments targetting specific molecular abnormalities.
Immunotherapy has shown limited effectiveness due to
the unique tumour environment in cHGG, and further
research is required to improve treatment strategies for
these rare tumours.
Keywords: Cerebellar glioma, high-grade glioma,
molecular therapies, immunotherapy.